Biohaven Pharmaceutical Holding Gross Margin 2016-2022 | BHVN

Current and historical gross margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current gross profit margin for Biohaven Pharmaceutical Holding as of March 31, 2022 is %.
Biohaven Pharmaceutical Holding Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.74B $0.63B 85.77%
2021-12-31 $0.46B $0.37B 80.13%
2021-09-30 $0.31B $0.24B 78.57%
2021-06-30 $0.19B $0.15B 76.32%
2021-03-31 $0.11B $0.08B 71.03%
2020-12-31 $0.06B $0.05B 71.88%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.996B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.981B 9.98
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $9.982B 15.76
Ginkgo Bioworks Holdings (DNA) United States $4.276B 0.00
Emergent Biosolutions (EBS) United States $1.424B 6.09
Arcus Biosciences (RCUS) United States $1.353B 34.31
Myovant Sciences (MYOV) United Kingdom $0.930B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.444B 0.00
Gelesis Holdings (GLS) United States $0.355B 0.00
Zymeworks (ZYME) Canada $0.299B 0.00
Ambrx Biopharma (AMAM) United States $0.138B 0.00
Enzo Biochem (ENZ) United States $0.118B 24.20
SQZ Biotechnologies (SQZ) United States $0.090B 0.00